Standard BioTools agrees to sell Microfluidics business to ARCHIMED
LAB•Standard BioTools agreed to sell its Microfluidics business to healthcare-focused investor ARCHIMED. Closing is targeted in about 30 days, subject to customary conditions, and the operations will remain within Standard BioTools until then.
1. Sale agreement
Standard BioTools agreed to sell its Microfluidics business to healthcare-focused investor ARCHIMED. The deal is targeted to close in about 30 days, subject to customary closing conditions; Microfluidics operations will remain within Standard BioTools until closing.
